Clinical Trial

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-11-18; most recent amendment 2026-02-03.
Status change: Recruiting → Active, Not Recruiting 2026-02-03
Trial Details
NCT Number NCT05126719
Lead Sponsor Shanghai Miracogen Inc.
Conditions Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment 238 participants
Start Date 2023-04-06
Primary Completion 2024-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-06